Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Seminars in Oncology|June 1, 2002
Increasing treatment options in indolent non-Hodgkin's lymphomaPhilippe Solal-CélignyLeukemia Research|June 6, 2006
Safety of rituximab maintenance therapy in follicular lymphomasPhilippe Solal-CélignyCurrent Opinion in Oncology|September 1, 2007
Maintenance therapy for low-grade lymphomas: has the time come?Guillaume Cartron, Philippe Solal-CélignyHaematologica|July 15, 2003
Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenanceYossi Cohen, Philippe Solal-Céligny, Aaron PolliackClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Interindividual variability of response to rituximab: from biological origins to individualized therapiesGuillaume Cartron, Ralf Ulrich Trappe, Philippe Solal-Céligny, et al.British Journal of Haematology|December 13, 2017
A retrospective study on the management of patients with rituximab refractory follicular lymphomaPhilippe Solal-Céligny, Pierre Leconte, Aurélie Bardet, et al.Anti-Cancer Drugs|April 25, 2003
Rituximab therapy for indolent non-Hodgkin's lymphomaAnton Hagenbeek, Myron S Czuczman, Michele Ghielmini, et al.Clinical Lymphoma, Myeloma & Leukemia|June 18, 2017
ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid MalignanciesGandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA studyCatherine Sebban, Pauline Brice, Richard Delarue, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN studyGilles A Salles, Franck Morschhauser, Philippe Solal-Céligny, et al.Pageof 2